

Nebraska Department of Health and Human Services

Health Alert Network

Advisory

4/30/2026

End of 2025-2026 seasonal RSV monoclonal antibody therapy recommendation

On March 27, 2026, the Nebraska Department of Health and Human Services (NDHHS) recommended providers to extend use of respiratory syncytial virus (RSV) monoclonal antibody therapies, nirsevimab (Beyfortus, Sanofi and AstraZeneca), and clesrovimab (Enflonia, Merck), through April 30, 2026, in response to elevated RSV activity in Nebraska at that time. **This recommendation will not be extended further for the 2025-2026 season; thus it will expire on May 1, 2026.** By not extending the RSV monoclonal antibody recommendation further, it will allow the eligible population, infants up to 8 months of age entering their first RSV season, a better window of protection when receiving the therapy during the 2026-2027 season compared to receiving it now. The RSV monoclonal antibody therapy recommendation will resume in the fall of 2026 for the start of the 2026-2027 season.

This decision is supported by NDHHS RSV surveillance data. In Nebraska, during 4/19/26–4/25/26, RSV test positivity was 9.7%, marking the fourth consecutive week-to-week decrease in RSV test positivity. This decision is further supported by NDHHS's syndromic surveillance data. This data is monitored weekly to track the number of RSV-associated visits to emergency departments and inpatient facility settings. In both settings, this data has decreased for four consecutive weeks and is 0.1% away from dropping below baseline levels, which are determined by calculating the average weekly percentage of RSV-associated visits among all patient visits over the past five years. This laboratory and syndromic surveillance data strengthens our indication that RSV activity levels continue to decline in Nebraska, and we expect that trend to continue in the coming weeks.

For updated RSV and other respiratory virus surveillance data, including surveillance data mentioned above, please visit [NDHHS's respiratory illness dashboard](#) or subscribe to [NDHHS's weekly respiratory disease data report](#).

Derek Julian, MPH
Respiratory Disease Epidemiologist
402-471-1376

Dr. Sydney R. Stein
State Epidemiologist
531-530-7276

Dr. Timothy Tesmer
CMO Public Health
402-471-8566

